Community Context and Psychological Flexibility in Residential Substance Use Treatment: A Longitudinal Sequential Mediation Study
NCT07926750, Active not recruiting, Under The Tree Therapeutic Community
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Community Context and Psychological Flexibility in Residential Substance Use Treatment: A Longitudinal Sequential Mediation Study | ClinicalTrials.gov |
| NCT number | NCT07926750 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Enrollment | 80 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Under The Tree Therapeutic Community | ClinicalTrials.gov |
| Conditions | Substance-Related Disorders, Substance Use Disorders | ClinicalTrials.gov |
| Interventions | Routine residential therapeutic community treatment (not assigned by the study) | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Sequential indirect effect of helplessness on negative automatic thoughts through avoidance and environmental reward (IE = a1 × a2 × b) | Weekly assessments from baseline through week 8, with additional weekly assessments through study completion for participants remaining in the study beyond week 8. | Within-person sequential indirect effect estimated in a multilevel longitudinal mediation model: helplessness at week t (X), avoidance at week t+1 (M1; Behavioral Activation for Depression Scale, avoidance/rumination subscale), environmental reward at week t+2 (M2; Environmental Reward Observation Scale), and negative automatic thoughts at week t+3 (Y; Automatic Thoughts Questionnaire-8). The effect is the product of paths a1, a2, and b, reported with a Monte Carlo confidence interval. Within-person and between-person effects are estimated separately. | ClinicalTrials.gov |
| Secondary | Moderation of the avoidance-to-environmental-reward path by community context | Baseline and weekly assessments through Week 8; additional weekly assessments through study completion (anticipated mean follow-up duration to be specified). | Interaction between avoidance at week t+1 and community context at week t predicting environmental reward at week t+2, measured using the Environmental Reward Observation Scale (EROS). The EROS consists of 10 items, each scored from 1 to 4, yielding a total score ranging from 10 to 40 points. Higher scores indicate greater perceived environmental reward and therefore represent a better outcome. The interaction coefficient will quantify whether community context moderates the within-person relationship between avoidance and subsequent environmental reward. Measurement Unit: Regression interaction coefficient (β), representing the change in the avoidance-to-environmental-reward relationship associated with community context. | ClinicalTrials.gov |
| Secondary | Within-person and between-person effects of psychological flexibility on environmental reward (Environmental Reward Observation Scale; EROS) | Baseline and assessments every 2 weeks through Week 8; additional assessments every 2 weeks through study completion (anticipated mean follow-up duration to be specified). | Multilevel longitudinal regression coefficients estimating the within-person and between-person effects of psychological flexibility, measured using \[name of psychological flexibility questionnaire\], on environmental reward measured using the Environmental Reward Observation Scale (EROS). The EROS consists of 10 items, each scored from 1 to 4, yielding a total score ranging from 10 to 40 points. Higher scores indicate greater perceived environmental reward and therefore represent a better outcome. Within-person and between-person effects of psychological flexibility will be estimated separately. | ClinicalTrials.gov |
| Secondary | Within-person and between-person effects of psychological flexibility on negative automatic thoughts (Automatic Thoughts Questionnaire-8; ATQ-8) | Baseline and assessments every 2 weeks through Week 8; additional assessments every 2 weeks through study completion (anticipated mean follow-up duration to be specified). | Multilevel longitudinal regression coefficients estimating the within-person and between-person effects of psychological flexibility, measured using \[name of psychological flexibility questionnaire\], on negative automatic thoughts measured using the Automatic Thoughts Questionnaire-8 (ATQ-8). The ATQ-8 consists of 8 items, each scored from 1 to 5, yielding a total score ranging from 8 to 40 points. Higher scores indicate greater frequency or intensity of negative automatic thoughts and therefore represent a worse outcome. Within-person and between-person effects of psychological flexibility will be estimated separately. | ClinicalTrials.gov |
| Secondary | Convergent and discriminant validity of language-derived indicators of helplessness and psychological flexibility | Weekly assessments from baseline through Week 8, with additional weekly assessments through study completion (anticipated mean follow-up duration to be specified). | Pearson correlation coefficients (r) or Spearman rank correlation coefficients (ρ), as appropriate, between natural language processing (NLP)-derived indicators of helplessness and psychological flexibility extracted from weekly written narratives and their corresponding questionnaire scores. Correlation coefficients will be reported separately for each construct. Additional correlations with prespecified surface text features (including narrative length and lexical characteristics) will be examined to assess the extent to which language-derived indicators depend on superficial textual properties. Measurement Units: Correlation coefficients (r or ρ), ranging from -1 to +1. | ClinicalTrials.gov |
| Other | Anxiety symptoms (Generalized Anxiety Disorder-7; GAD-7) | Baseline and assessments every 2 weeks through Week 8, with additional assessments every 2 weeks through study completion (anticipated mean follow-up duration to be specified). | Total score on the Generalized Anxiety Disorder 7-item scale (GAD-7), used as a covariate in longitudinal analyses and as a secondary outcome measure. The scale consists of 7 items, each scored from 0 to 3, yielding a total score ranging from 0 to 21. Higher scores indicate greater anxiety symptom severity and therefore represent a worse outcome. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)